What is Wedbush’s Forecast for ZNTL FY2024 Earnings?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Wedbush raised their FY2024 earnings estimates for shares of Zentalis Pharmaceuticals in a report issued on Wednesday, January 29th. Wedbush analyst R. Driscoll now forecasts that the company will earn ($2.25) per share for the year, up from their prior estimate of ($2.33). Wedbush currently has a “Neutral” rating and a $4.00 price objective on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q4 2024 earnings at ($0.58) EPS, Q1 2025 earnings at ($0.54) EPS, Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.97) EPS, FY2026 earnings at ($1.63) EPS, FY2027 earnings at ($1.32) EPS and FY2028 earnings at ($0.63) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.36.

Several other equities analysts have also recently issued reports on the company. HC Wainwright reduced their price objective on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, January 29th. Wells Fargo & Company decreased their price objective on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Guggenheim dropped their target price on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a report on Friday, November 15th. Finally, UBS Group reduced their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, Zentalis Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $8.24.

Zentalis Pharmaceuticals Trading Down 3.0 %

Shares of ZNTL opened at $1.63 on Monday. The stock’s 50 day moving average is $2.87 and its two-hundred day moving average is $3.23. Zentalis Pharmaceuticals has a twelve month low of $1.61 and a twelve month high of $18.07. The firm has a market capitalization of $116.16 million, a PE ratio of -0.65 and a beta of 1.86.

Insider Buying and Selling

In other news, Director Jan Skvarka acquired 60,000 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Friday, January 31st. The shares were purchased at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the purchase, the director now directly owns 149,551 shares of the company’s stock, valued at $257,227.72. This trade represents a 67.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several large investors have recently added to or reduced their stakes in ZNTL. Erste Asset Management GmbH bought a new stake in Zentalis Pharmaceuticals in the third quarter worth about $37,000. Paloma Partners Management Co bought a new position in Zentalis Pharmaceuticals during the third quarter valued at approximately $37,000. Aigen Investment Management LP acquired a new stake in shares of Zentalis Pharmaceuticals in the third quarter worth about $41,000. Capstone Investment Advisors LLC bought a new stake in shares of Zentalis Pharmaceuticals during the 3rd quarter worth $48,000. Finally, China Universal Asset Management Co. Ltd. increased its position in Zentalis Pharmaceuticals by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after buying an additional 5,333 shares during the period.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.